A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.
CStone Pharmaceuticals ( OTCPK:CSPHF) Discusses CS2009 Data Interpretation and Future Clinical Development Strategy October 20, 2025 9:00 AM EDT ...
Excessive signaling by platelet-derived growth factor receptor (PDGFR)-α, a transmembrane tyrosine kinase, helps drive the ...
Keytruda plus Lenvima demonstrates durable 5-year survival benefit versus chemotherapy for patients with advanced endometrial carcinoma following one prior platinum-based regimen: ...
Drug candidates spanning oncology, neurology, rare diseases and more are approaching critical development as the calendar turns to 2026.
The progression-free survival (PFS) hazard ratio (HR) was 0.60 (p < 0.0001) for ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy. The median PFS was 11.14 months in the ivonescimab ...
RENALuT is a phase 2, single-arm trial evaluating the efficacy of [177Lu]Lu-PSMA-617 in patients with second- or third-line metastatic clear cell renal cell carcinoma (ccRCC). The study explores a ...
Akeso Inc. (9926.HK) today announced that the groundbreaking results from the registrational Phase III AK112-306/HARMONi-6 ...
According to Sam Altman, your web browser is outdated. “AI represents a rare, once-a-decade opportunity to rethink what a ...
Texas A&M researchers found that in an aggressive kidney cancer, RNA builds “droplet hubs” that activate tumor genes. By creating a molecular switch to dissolve these hubs, they stopped cancer growth ...
The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback